Abstract: in an experiment on 10 mongrel dogs (female), an analysis of the dynamics of the content of ceftriaxone in the peripheral blood after intramuscular and intranodular endolymphatic insertion was carried out against the background of modeling the inflammatory process in the uterine horn. In accordance with the “Rules for conducting research using experimental animals” of the Ministry of Health of the Russian Federation and the Russian Federation keeping animals in standard vivarium conditions, in compliance with the “Laboratory Practice Rules for Preclinical Research in the Russian Federation” and international recommendations of the European Convention for the Protection of Vertebrate Animals used in experimental research two series of experimental studies were performed against the background of an experimental model of the inflammatory process in the uterus. In series I, ceftriaxone was injected intramuscularly in 5 animals for the treatment of the inflammatory process in the uterus at the rate of 25 μg per 1 kg of animal weight once a day. In series II of 5 animals, ceftriaxone was injected intra-laterally endolymphatically into the popliteal lymph node at the rate of 25 μg per 1 kg of animal weight once a day. Intranodular insertion of ceftriaxone was performed by puncture into the popliteal lymph node. After sanitation of the experimental focus of inflammation in the uterine horn for 1 day, blood was taken from the vein and material from the focus of inflammation 3, 6, 9, 12, 18, 24 hours after the insertion of the antibiotic. It was found that after intramuscular administration, the content of ceftriaxone in the material from the focus of inflammation during the first 3 hours, the concentration significantly exceeded the minimum inhibitory concentration (P <0.05), after 6 hours these differences became insignificant (P˃0.05), and more later terms became less than the minimum inhibitory concentration. After endolymphatic administration for 12 hours, the content of ceftriaxone in the inflammatory focus significantly exceeded the minimum inhibitory concentration (P <0.05), after 18 hours the differences became insignificant (P˃0.05), but the drug level exceeded the minimum inhibitory concentration. Thus, the frequency of intramuscular administration of ceftriaxone to maintain a therapeutic concentration in the focus of inflammation in the treatment of inflammatory gynecological diseases should be 4 times a day, and with endolymphatic insertion at least 2 times a day. The endolymphatic insertion of ceftriaxone in the treatment of infectious gynecological diseases is pathogenetically substantiated. It is advisable to continue research in this direction.
Keywords: inflammatory gynecological diseases, endolymphatic injection, intramuscular injection, antibiotic therapy, ceftriaxone